{"classes":[{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric mean and geometric coefficient of variation were not reported for n \\< 3.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"57","value":"0.006045"},{"groupId":"OG003","spread":"14","value":"0.004984"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 4 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"CL for IV dosing. CL was calculated by dose / AUCtau for Cycles 1 and 4 IV dosing. AUCtau was defined as area under the serum concentration time profile from time zero to time tau, the dosing interval, where tau = 504 hours for every 3 weeks (Q3W) IV dosing reporting arm.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"OG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"OG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"OG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"OG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis population included all enrolled participants treated who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1 and 24 hours post dose on Cycle 1 Day 1, and pre-dose and 1 hour post dose on Cycle 4 Day 1 in Part 1","title":"Clearance (CL) of PF-06801591 - Part 1","type":"SECONDARY","unitOfMeasure":"L/hr"}